Skip to main content
BRIM logo

BRIM — Investor Relations & Filings

Ticker · 6885 ISIN · TW0006885007 TW Professional, scientific and technical activities
Open in API
Filings indexed 19 across all filing types
Latest filing 2026-04-08 Director's Dealing
Country TW Taiwan
Listing TW 6885

About BRIM

https://www.brimbiotech.com/

BRIM Biotechnology, Inc. specializes in the application of translational science to develop innovative therapies for unmet medical needs. The company utilizes its proprietary Pigment Epithelium-Derived Factor (PEDF) Derived Short Peptide (PDSP) technology platform, which leverages neurotrophic properties to stimulate cell proliferation, wound healing, and tissue regeneration. Its research pipeline primarily targets ophthalmology and degenerative conditions, featuring lead candidates such as BRM421 for dry eye syndrome, BRM424 for neurotrophic keratitis, and BRM521 for osteoarthritis. Operating through an integrated model, the company advances drug candidates to the proof-of-concept stage before pursuing strategic licensing and partnerships for late-stage development. BRIM also incorporates precision medicine and bioinformatics to explore combination therapies and enhance therapeutic outcomes.

Recent filings

Filing Released Lang Actions
115年03月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document is a detailed disclosure of insider (董事長、董事、獨立董事、總經理、副總經理等) shareholdings and month-on-month changes in their personal stock positions, provided by the listed company 全福生技 on Taiwan’s Public Information Observatory. It reports personal share transactions by directors and executives, which falls under insider dealing disclosures rather than company buybacks or major external shareholding notifications. Therefore, it should be classified as a Director’s Dealing (DIRS).
2026-04-08 Chinese
115年03月董事會成員及持股
Director's Dealing Classification · 85% confidence The document is a regulatory disclosure from the public information observation station listing shareholdings and pledge status of directors, independent directors, the general manager, and other insiders of 全福生技. It is an insider shareholding change report (“內部人持股異動事後申報表”), which falls under reports of personal share transactions by company directors and executives. This matches the “Director’s Dealing” category (DIRS).
2026-04-08 Chinese
115年3月背書保證與資金貸與
Regulatory Filings Classification · 75% confidence The document is a short, periodic tabular disclosure of fund loan balances and endorsement/guarantee information provided on Taiwan’s MOPS (“公開資訊觀測站”) by a listed company. It does not present a full financial report, dividend notice, share issue, or other specific transaction, but rather a regulatory-required update. Therefore it falls under the general “Regulatory Filings” category (RNS).
2026-04-07 Chinese
115年3月營業收入
Fund Information / Factsheet Classification · 90% confidence The document is a brief financial summary showing monthly and cumulative net operating revenue figures for a company named 全福生技 for the period 民國115年03月 (March 2026). It includes percentage changes compared to the previous year and explanations for revenue changes. The document is very short (774 characters) and resembles a revenue summary or factsheet rather than a full financial report. There is no indication of detailed financial statements, management discussion, or regulatory certifications. It does not announce a report publication but provides direct financial data. Given the concise nature and content, this fits best as a Fund Information / Factsheet (FS) type document, which is a brief summary of key company financials and market info.
2026-04-07 Chinese

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.